Smoking Prevalence at a University Hospital

Status Completed

Clinical Trial Summary

- Tobacco is the leading risk factor for avoidable mortality in France and around the world. It is also the second cause of life with disability in the world and the leading preventable risk factor for cancer in France and worldwide.

- The "Health Barometer" studies carried out for 25 years in France by Santé-Publique France assessed prevalence of smoking in the lay population. These studies showed that smoking prevalence has stabilized among 15-75 year olds (34.1% of current smokers) with a slight decrease in regular smoking (from 29.1% in 2010 to 28.2% in 2014).

- Data on the prevalence of smoking among hospital staff are contradictory. Some studies find a higher prevalence of active smoking than the general population; others have a lower prevalence. However, it appears that an active prevention policy with hospital staff can significantly and rapidly reduce the prevalence of active smoking.

- The prevalence of active smoking in patients is logically higher than in the general population (at comparable age).

- The data on the prevalence of smoking among medical students are also contradictory. Yet, this population is a special interest group given their future investment in patient care.

- Cannabis use also appears to be an independent risk factor for respiratory diseases and broncho-pulmonary cancers. Cannabis use among health students is not uncommon (11.5% of students). To our knowledge, the measurement of the prevalence of Cannabis use in an all-patient population of a hospital-university facility has never been achieved.

- According to the health barometer 2014, about a quarter of 15-75 year olds have already tried electronic cigarettes and 6% are regular current users. Although the toxicity of the electronic cigarette and its interest in weaning remain controversial, its use to patients, staff or patients has been reported very little.

The aim of this study is to assess the impact of collective and individual tobacco control measures by measuring the prevalence of smoking on a given day at the "Hospices Civils de Lyon", among patients, staff and students present on a given day.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Tobacco Smoking

Clinical Trial Details

NCT number	NCT03268980
Study type	Observational
Source	Hospices Civils de Lyon
Contact
Status	Completed
Phase
Start date	November 23, 2017
Completion date	November 23, 2017

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05415371` - Persistent Poverty Counties Pregnant Women With Medicaid	N/A
Recruiting	`NCT04038255` - Mindfulness Based Smoking Cessation Among Cancer Survivors	Phase 4
Completed	`NCT04123041` - Characterize the Nicotine Uptake and Subjective Effects With Use of JUUL Electronic Nicotine Delivery Systems	N/A
Completed	`NCT02735382` - EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study	N/A
Completed	`NCT02139930` - Project 2: Strategies for Reducing Nicotine Content in Cigarettes	N/A
Completed	`NCT04107779` - Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS	N/A
Completed	`NCT05037656` - Testing a School-Based E-cigarette, Tobacco, and Betel (Areca) Nut Use Prevention Curriculum for Guam Youths	N/A
Completed	`NCT04200157` - Testing the Decoy Effect to Increase Tobacco Treatment Uptake
Enrolling by invitation	`NCT06042361` - Enhancing Equity in Smoke-free Housing	N/A
Completed	`NCT02841683` - Pragmatic Randomised Controlled Trial Evaluating Effectiveness of a Smoking Cessation e- Intervention " Tabac Info Service "	N/A
Completed	`NCT03151421` - Air Quality Feedback to Reduce Second-hand Smoke (SHS) Exposure in the Home	N/A
Completed	`NCT04104152` - CSD190203: A Study to Determine Subject Puffing Patterns of an Electronic Nicotine Delivery System in an Ambulatory Setting	N/A
Recruiting	`NCT05306158` - Dual Use Approach Bias Training for Nicotine Addiction	N/A
Completed	`NCT04094363` - CSD190202: Study to Assess Elements of Abuse Liability for Two Electronic Nicotine Delivery Systems	N/A
Completed	`NCT04143256` - Evaluating Selected Constituents in the Exhaled Breath Samples	N/A
Completed	`NCT03553992` - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers	N/A
Completed	`NCT05102786` - CSD210904: Study to Assess Actual Use of a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in Current Adult Smokers
Terminated	`NCT04396847` - Laboratory Screening of Lorcaserin for Alcohol Use Disorder	Phase 2
Completed	`NCT03694327` - Innovative Digital Therapeutic for Smoking Cessation	N/A
Completed	`NCT05030194` - Comparing Nicotine Delivery, Subjective Effects, and Sensory Experiences of Tobacco Users Using Oral Nicotine Products and Electronic Cigarettes [ZYN Study]	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Smoking Prevalence at a University Hospital — TABAC-HCL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms